Profit outpacing revenue
Profit grew 62.0% while revenue grew 23.1%, so the company kept more of each rupee of revenue as profit.
Importance 72 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit grew 62.0% while revenue grew 23.1%, so the company kept more of each rupee of revenue as profit.
Importance 72 / 95 · growth
Profit has swung sharply over 7 years (from ₹-1,509 to ₹5,355) — one year is a weak guide to the earnings power.
Importance 65 / 95 · growth
Cash conversion (CFO ÷ profit) has averaged 1.11× over the last 3 profit-making years versus 2.66× before that.
Importance 64 / 95 · cash quality
EBITDA margin of 33.1% is the widest in 7 years (prior range 2.6% to 24.1%).
Importance 62 / 95 · profitability
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 7.9% a year over 7 years, from ₹16,369 cr in FY2019 to ₹27,958 cr in FY2026. Net profit grew 36.2% a year over the same period.
Profit grew 62.0% while revenue grew 23.1%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
Profit has swung sharply over 7 years (from ₹-1,509 to ₹5,355) — one year is a weak guide to the earnings power.
Over 7 years profit compounded at 36.2% a year while revenue compounded at 7.9% a year — though FY2024 saw a one-off step-change of 332% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit grew 62.0% year on year (FY2025 → FY2026).
Revenue grew 23.1% year on year (FY2025 → FY2026).
Revenue has compounded at 7.9% a year over 7 years (₹16,369 → ₹27,958) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹7,827 cr (up 11.1% on the same quarter last year) and net profit ₹1,155 cr (down 22.2%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹1,155 cr, down 22.2% from ₹1,485 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 EBITDA margin was 27.7%, down 6.76 percentage points from 34.5% a year earlier.
Rule QTR_MARGIN_CHANGED_YOY
Q2 FY27 net profit declined 22.2% while revenue grew 11.1% vs the same quarter last year — a gap of 33.3 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 5,768 | +11.0% | 859 | +38.8% | 14.9% |
| Q4 FY25 | 5,667 | +14.2% | 782 | +112.5% | 13.8% |
| Q1 FY26 | 6,268 | +11.9% | 1,221 | +51.6% | 19.5% |
| Q2 FY26 | 7,048 | +24.2% | 1,485 | +72.8% | 21.1% |
| Q3 FY26 | 7,168 | +24.3% | 1,181 | +37.5% | 16.5% |
| Q4 FY26 | 7,475 | +31.9% | 1,469 | +87.7% | 19.6% |
| Q1 FY27 | 8,277 | +32.0% | 1,417 | +16.0% | 17.1% |
| Q2 FY27 | 7,827 | +11.1% | 1,155 | −22.2% | 14.8% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 33.1% in FY2026, against 19.8% in FY2019. ROE was 26.9% and ROCE 31.0% in FY2026.
EBITDA margin of 33.1% is the widest in 7 years (prior range 2.6% to 24.1%).
Rule MARGIN_AT_MULTI_YEAR_HIGH
ROE of 26.9% is the highest in 7 years (prior range -11.6% to 20.9%).
ROE of 26.9% is well above the pharmaceuticals median of 14.4%.
EBITDA margin improved from 24.1% to 33.1% of revenue.
ROE improved from 20.9% to 26.9% year on year.
Debt-to-equity was 0.26x in FY2026, against 0.60x in FY2019; interest coverage 18.10x. Operating cash flow was 1.41x net profit.
Cash conversion (CFO ÷ profit) has averaged 1.11× over the last 3 profit-making years versus 2.66× before that.
Rule CASH_CONVERSION_DETERIORATING
Total debt is down from ₹8,222 to ₹5,910 over 7 years (28.1% lower); debt-to-equity moved 0.60× → 0.26×.
Operating cash flow has matched or exceeded reported profit in 4 of the last 5 profit-making years (latest 1.41×).
Free cash flow has been positive in 5 of the last 6 years.
Within its 12-company Pharmaceuticals peer group, it ranks 1 of 12 on return on equity and 4 of 12 on EBITDA margin. Its P/E of 17.6 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
LUPIN · 2nd of 12 · set median 14.8%
LUPIN · 4th of 12 · set median 28.7%
LUPIN · 1st of 12 · set median 14.4%
LUPIN · 1st of 12 · set median 45.3×
ROE of 26.9% beats the pharmaceuticals median (14.4%) while P/B (4.08×) sits below it (4.74×).
Rule STRONG_RETURNS_AT_DISCOUNT
On the trailing twelve months. Last full year: P/E 17.2× · P/S 3.2× · ROE 26.9%.
The share price is down 1.0% over 1 year, up 64.5% over 3 years (18.1% a year) and up 124% over 5 years (17.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 20.1% below its 52-week high.
Over 5 years profit compounded at 34.3% a year while the stock returned 17.5% a year.
Rule STOCK_LAGGED_EARNINGS
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16,369 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 |
| Total income | 17,082 | 15,859 | 15,299 | 16,547 | 16,715 | 20,131 | 22,904 | 28,382 |
| EBITDA | 3,246 | 2,839 | 2,703 | 429 | 1,871 | 3,931 | 5,479 | 9,240 |
| Profit before tax | 1,517 | 753 | 1,675 | −1,373 | 716 | 2,422 | 4,015 | 6,873 |
| Net profit | 615 | −270 | 1,228 | −1,509 | 448 | 1,936 | 3,306 | 5,355 |
| EPS (₹) | 34.3 | −6.0 | 27.1 | −33.6 | 9.5 | 42.0 | 72.0 | 116.8 |
| Net worth | 13,789 | 12,581 | 13,858 | 12,222 | 12,543 | 14,373 | 17,294 | 22,513 |
| Total debt | 8,222 | 4,286 | 3,066 | 3,844 | 4,244 | 2,670 | 5,077 | 5,910 |
| Operating cash flow | — | — | 1,239 | 1,082 | 1,934 | 3,490 | 430 | 7,546 |
| Free cash flow | — | — | 562 | 184 | 473 | 2,574 | −1,223 | 5,738 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | -6.1 | -1.4 | 8.2 | 1.4 | 20.2 | 13.5 | 23.1 |
| Profit growth YoY | — | -143.8 | — | -222.9 | — | 332.3 | 70.8 | 62.0 |
| Profitability | ||||||||
| EBITDA margin % | 19.8 | 18.5 | 17.8 | 2.6 | 11.2 | 19.6 | 24.1 | 33.1 |
| Net margin % | 3.6 | -1.7 | 8.0 | -9.1 | 2.7 | 9.6 | 14.4 | 18.9 |
| Return on equity % | 4.5 | -2.0 | 9.3 | -11.6 | 3.6 | 14.4 | 20.9 | 26.9 |
| Return on capital % | 9.8 | 9.6 | 10.7 | -7.5 | 6.0 | 16.2 | 21.9 | 31.0 |
| Leverage & cash | ||||||||
| Debt to equity | 0.60 | 0.34 | 0.22 | 0.31 | 0.34 | 0.19 | 0.29 | 0.26 |
| Cash flow ÷ profit | — | — | 1.01 | — | 4.32 | 1.80 | 0.13 | 1.41 |
| Current ratio | 2.26 | 1.67 | 1.66 | 1.51 | 1.34 | 1.58 | 1.87 | 1.90 |